Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Accumulated Expenses for 9 consecutive years, with $40.1 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 543.63% year-over-year to $40.1 million; the TTM value through Mar 2026 reached $40.1 million, up 543.63%, while the annual FY2025 figure was $17.0 million, 4.47% up from the prior year.
  • Accumulated Expenses hit $40.1 million in Q1 2026 for Bicycle Therapeutics, up from $17.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $44.4 million in Q3 2025 and bottomed at $2.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $15.9 million, with a median of $13.0 million recorded in 2024.
  • Year-over-year, Accumulated Expenses surged 844.27% in 2023 and then tumbled 78.01% in 2024.
  • Bicycle Therapeutics' Accumulated Expenses stood at $26.5 million in 2022, then plummeted by 49.36% to $13.4 million in 2023, then grew by 21.49% to $16.3 million in 2024, then increased by 4.47% to $17.0 million in 2025, then surged by 136.02% to $40.1 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $40.1 million, $17.0 million, and $44.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.